Keywords
Last Name
Institution

David Fishman

TitlePROFESSOR
InstitutionMount Sinai
DepartmentObstetrics, Gynecology and Reproductive Science
Address5 East 98th Street
New York NY 10029
Phone212-241-7952
Fax212-241-4787

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G, Difeo A. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014 Jan 7; 5:2977.
      View in: PubMed
    2. Lee S, Yang Y, Fishman D, Banaszak Holl MM, Hong S. Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. J Phys Chem B. 2013 Aug 8; 117(31):9233-40.
      View in: PubMed
    3. Nguyen L, Cardenas-Goicoechea SJ, Gordon P, Curtin C, Momeni M, Chuang L, Fishman D. Biomarkers for early detection of ovarian cancer. Womens Health (Lond Engl). 2013 Mar; 9(2):171-85; quiz 186-7.
      View in: PubMed
    4. Momeni M, Kolev V, Cardenas-Goicoechea J, Getrajdman J, Fishman D, Chuang L, Kalir T, Rahaman J, Zakashansky K. Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens? Am J Obstet Gynecol. 2013 Jan; 208(1):71.e1-6.
      View in: PubMed
    5. Fleischer AC, Lyshchik A, Hirari M, Moore RD, Abramson RG, Fishman DA. Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: recent advances and potential improvements. J Oncol. 2012; 2012:302858.
      View in: PubMed
    6. Dutta S, Wang FQ, Wu HS, Mukherjee TJ, Fishman DA. The NF-?B pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecol Oncol. 2011 Oct; 123(1):129-37.
      View in: PubMed
    7. Wu HS, Wang FQ, Smicun Y, Fishman D. Recognition of linear stress fibers based on Hough transform. Anal Quant Cytol Histol. 2011 Jun; 33(3):121-31.
      View in: PubMed
    8. Wang FQ, Fisher J, Fishman DA. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol. 2011 Feb; 120(2):247-55.
      View in: PubMed
    9. Dutta S, Wang FQ, Fishman DA. The dire need to develop a clinically validated screening method for the detection of early-stage ovarian cancer. Biomark Med. 2010 Jun; 4(3):437-9.
      View in: PubMed
    10. Dutta S, Wang FQ, Phalen A, Fishman DA. Biomarkers for ovarian cancer detection and therapy. Cancer Biol Ther. 2010 May 1; 9(9):668-77.
      View in: PubMed
    11. Dutta S, Wang FQ, Fleischer AC, Fishman DA. New frontiers for ovarian cancer risk evaluation: proteomics and contrast-enhanced ultrasound. AJR Am J Roentgenol. 2010 Feb; 194(2):349-54.
      View in: PubMed
    12. Fleischer AC, Lyshchik A, Andreotti RF, Hwang M, Jones HW, Fishman DA. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles. AJR Am J Roentgenol. 2010 Feb; 194(2):343-8.
      View in: PubMed
    13. Wang FQ, Ariztia EV, Boyd LR, Horton FR, Smicun Y, Hetherington JA, Smith PJ, Fishman DA. Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol. 2010 Apr; 117(1):88-95.
      View in: PubMed
    14. Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol. 2009 Dec; 5(10):1659-73.
      View in: PubMed
    15. Rahaman J, Steiner N, Hayes MP, Chuang L, Fishman D, Gretz Iii H. Chemotherapy for gynecologic cancers. Mt Sinai J Med. 2009 Dec; 76(6):577-88.
      View in: PubMed
    16. Fleischer AC, Lyshchik A, Jones HW, Crispens MA, Andreotti RF, Williams PK, Fishman DA. Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography. J Ultrasound Med. 2009 Oct; 28(10):1273-80.
      View in: PubMed
    17. Wang FQ, Barfield E, Dutta S, Pua T, Fishman DA. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol. 2009 Dec; 115(3):414-23.
      View in: PubMed
    18. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. Biological significance of prolactin in gynecologic cancers. Cancer Res. 2009 Jun 15; 69(12):5226-33.
      View in: PubMed
    19. Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, Liu D, Rademaker A, Fishman DA, Podratz KC, Reiter JL, Maihle NJ. Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer. Cancer Treat Res. 2009; 149:189-202.
      View in: PubMed
    20. Wang F, Fishman DA. Lysophosphatidic acid and invasion. Cancer Treat Res. 2009; 149:269-96.
      View in: PubMed
    21. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA. LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol. 2009 Jan; 112(1):215-23.
      View in: PubMed
    22. Gogoi R, Kudla M, Gil O, Fishman D. The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion. Reprod Sci. 2008 Oct; 15(8):846-52.
      View in: PubMed
    23. Fleischer AC, Lyshchik A, Jones HW, Crispens M, Loveless M, Andreotti RF, Williams PK, Fishman DA. Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. J Ultrasound Med. 2008 Jul; 27(7):1011-8; quiz 1019-21.
      View in: PubMed
    24. Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, Stack MS, Hudson LG. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res. 2008 Jun 15; 68(12):4606-13.
      View in: PubMed
    25. Devine KM, Smicun Y, Hope JM, Fishman DA. S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac. Gynecol Oncol. 2008 Aug; 110(2):237-45.
      View in: PubMed
    26. Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, Smith-McCune K, Fishman D, Gray JW, Mills GB. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol. 2008 Aug; 2(2):164-81.
      View in: PubMed
    27. Gil OD, Lee C, Ariztia EV, Wang FQ, Smith PJ, Hope JM, Fishman DA. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner. Gynecol Oncol. 2008 Feb; 108(2):361-9.
      View in: PubMed
    28. Liu C, Shea N, Rucker S, Harvey L, Russo P, Saul R, Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Fishman D, Vonderheid E, Booher S, Cowen EW, Hwang ST, Whiteley GR. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics. 2007 Nov; 7(22):4045-52.
      View in: PubMed
    29. Fisher WG, Rosenblatt KP, Fishman DA, Whiteley GR, Mikulskis A, Kuzdzal SA, Lopez MF, Tan NC, German DC, Garner HR. A robust biomarker discovery pipeline for high-performance mass spectrometry data. J Bioinform Comput Biol. 2007 Oct; 5(5):1023-45.
      View in: PubMed
    30. Smicun Y, Gil O, Devine K, Fishman DA. S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells. Gynecol Oncol. 2007 Nov; 107(2):298-309.
      View in: PubMed
    31. Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Petricoin EF, Liotta LA, Patton WF, Whiteley GR, Rosenblatt K, Gurnani P, Nandi A, Neill S, Cullen S, O'Gorman M, Sarracino D, Lynch C, Johnson A, Mckenzie W, Fishman D. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem. 2007 Jun; 53(6):1067-74.
      View in: PubMed
    32. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007 Apr 1; 67(7):3074-84.
      View in: PubMed
    33. Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, Hudson LG, Stack MS. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 2007 Mar 1; 67(5):2030-9.
      View in: PubMed
    34. Fedida S, Fishman D, Suzlovich Z, Argov S, Friger M, Oren L, Segal S, Sion-Vardy N. Impaired access of lymphocytes to neoplastic prostate tissue is associated with neoangiogenesis in the tumour site. Br J Cancer. 2007 Mar 26; 96(6):980-5.
      View in: PubMed
    35. Wu B, Abbott T, Fishman D, McMurray W, Mor G, Stone K, Ward D, Williams K, Zhao H. Ovarian cancer classification based on mass spectrometry analysis of sera. Cancer Inform. 2006; 2:123-32.
      View in: PubMed
    36. Zankl A, Pachman L, Poznanski A, Bonafé L, Wang F, Shusterman Y, Fishman DA, Superti-Furga A. Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome. J Bone Miner Res. 2007 Feb; 22(2):329-33.
      View in: PubMed
    37. Do TV, Symowicz JC, Berman DM, Liotta LA, Petricoin EF, Stack MS, Fishman DA. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res. 2007 Feb; 5(2):121-31.
      View in: PubMed
    38. Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2007 Oct; 105(2):221-8.
      View in: PubMed
    39. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007 Jan; 8(1):26-34.
      View in: PubMed
    40. Lee CJ, Ariztia EV, Fishman DA. Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer. Crit Rev Clin Lab Sci. 2007; 44(1):87-114.
      View in: PubMed
    41. Wang FQ, Smicun Y, Calluzzo N, Fishman DA. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Mol Cancer Res. 2006 Nov; 4(11):831-41.
      View in: PubMed
    42. Smicun Y, Reierstad S, Wang FQ, Lee C, Fishman DA. S1P regulation of ovarian carcinoma invasiveness. Gynecol Oncol. 2006 Dec; 103(3):952-9.
      View in: PubMed
    43. Gogoi R, Srinivasan S, Fishman DA. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert Rev Mol Diagn. 2006 Jul; 6(4):627-37.
      View in: PubMed
    44. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer. 2006 Feb 15; 118(4):879-88.
      View in: PubMed
    45. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006 Jan 15; 66(2):1181-90.
      View in: PubMed
    46. Ariztia EV, Lee CJ, Gogoi R, Fishman DA. The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci. 2006; 43(5-6):393-425.
      View in: PubMed
    47. Fishman D, Bazarsky E, Sneir R, Klement E, Orr N, Kayouf R, Segal S, El-On J. The flow-cytometry-based evaluation of cellular immunity in cases of cutaneous leishmaniasis and healthy controls from the endemic area in southern Israel. Ann Trop Med Parasitol. 2006 Jan; 100(1):23-31.
      View in: PubMed
    48. Kang S, Luo R, Smicun Y, Fishman DA, Meng Y. Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation. FEBS Lett. 2006 Jan 23; 580(2):443-9.
      View in: PubMed
    49. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 1; 11(17):6116-26.
      View in: PubMed
    50. Lowenthal MS, Mehta AI, Frogale K, Bandle RW, Araujo RP, Hood BL, Veenstra TD, Conrads TP, Goldsmith P, Fishman D, Petricoin EF, Liotta LA. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem. 2005 Oct; 51(10):1933-45.
      View in: PubMed
    51. Wang F, Reierstad S, Fishman DA. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett. 2006 May 18; 236(2):292-301.
      View in: PubMed
    52. So J, Wang FQ, Navari J, Schreher J, Fishman DA. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol. 2005 Jun; 97(3):870-8.
      View in: PubMed
    53. Petricoin EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005 May 20; 23(15):3614-21.
      View in: PubMed
    54. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005 Apr; 192(4):1214-21; discussion 1221-2.
      View in: PubMed
    55. Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, Fishman DA, Naftolin F. Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett. 2005 Mar 18; 220(1):57-65.
      View in: PubMed
    56. Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005 Mar 10; 114(1):19-31.
      View in: PubMed
    57. Liotta LA, Lowenthal M, Mehta A, Conrads TP, Veenstra TD, Fishman DA, Petricoin EF. Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst. 2005 Feb 16; 97(4):310-4.
      View in: PubMed
    58. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2):306-18.
      View in: PubMed
    59. Meng Y, Kang S, So J, Reierstad S, Fishman DA. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecol Oncol. 2005 Feb; 96(2):462-9.
      View in: PubMed
    60. Meng Y, Kang S, Fishman DA. Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer. FEBS Lett. 2005 Feb 14; 579(5):1311-9.
      View in: PubMed
    61. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005 Apr; 4(4):346-55.
      View in: PubMed
    62. Meng Y, Kang S, Fishman DA. Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells. Cancer Immunol Immunother. 2005 Aug; 54(8):807-14.
      View in: PubMed
    63. Meng Y, Graves L, Do TV, So J, Fishman DA. Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes. Gynecol Oncol. 2004 Dec; 95(3):488-95.
      View in: PubMed
    64. Alvero AB, Fishman DA, Qumsiyeh MB, Garg M, Kacinski BM, Sapi E. Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. J Soc Gynecol Investig. 2004 Dec; 11(8):553-61.
      View in: PubMed
    65. Elhyany S, Assa-Kunik E, Tsory S, Muller T, Fedida S, Segal S, Fishman D. The integrity of cholesterol-enriched microdomains is essential for the constitutive high activity of protein kinase B in tumour cells. Biochem Soc Trans. 2004 Nov; 32(Pt 5):837-9.
      View in: PubMed
    66. So J, Navari J, Wang FQ, Fishman DA. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol. 2004 Nov; 95(2):314-22.
      View in: PubMed
    67. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 2004 Nov; 10(11):1251-6.
      View in: PubMed
    68. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res. 2004 Oct 1; 64(19):7045-9.
      View in: PubMed
    69. Petricoin EF, Fishman DA, Conrads TP, Veenstra TD, Liotta LA. Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics. 2004 Aug; 4(8):2357-60.
      View in: PubMed
    70. Johann DJ, McGuigan MD, Patel AR, Tomov S, Ross S, Conrads TP, Veenstra TD, Fishman DA, Whiteley GR, Petricoin EF, Liotta LA. Clinical proteomics and biomarker discovery. Ann N Y Acad Sci. 2004 Jun; 1022:295-305.
      View in: PubMed
    71. Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G, Barrett JC, Liotta LA, Petricoin EF, Veenstra TD. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer. 2004 Jun; 11(2):163-78.
      View in: PubMed
    72. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004 May 15; 10(10):3291-300.
      View in: PubMed
    73. Calhoun EA, Fishman DA, Lurain JR, Welshman EE, Bennett CL. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004 Apr; 93(1):164-9.
      View in: PubMed
    74. Sandruck J, Escobar P, Lurain J, Fishman D. Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature. Gynecol Oncol. 2004 Feb; 92(2):701-4.
      View in: PubMed
    75. Fishman D, Elhyany S, Segal S. Non-immune functions of MHC class I glycoproteins in normal and malignant cells. Folia Biol (Praha). 2004; 50(2):35-42.
      View in: PubMed
    76. Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol. 2003 Dec; 91(3):552-7.
      View in: PubMed
    77. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 2003 Nov; 3(11):2085-90.
      View in: PubMed
    78. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003 Nov-Dec; 13(6):741-8.
      View in: PubMed
    79. O'Rourke Tiffen J, Pfeifer K, Fishman DA. Genetic risk assessment for breast and ovarian cancer. Adv Nurse Pract. 2003 Oct; 11(10):40-8.
      View in: PubMed
    80. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res. 2003 Sep 1; 9(10 Pt 1):3534-45.
      View in: PubMed
    81. Wu B, Abbott T, Fishman D, McMurray W, Mor G, Stone K, Ward D, Williams K, Zhao H. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics. 2003 Sep 1; 19(13):1636-43.
      View in: PubMed
    82. Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, Wheeler JE, Wonderlick A, Fishman D, Karlan B, Risch H, Cramer DW, Dube MP, Narod SA. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control. 2003 Jun; 14(5):439-46.
      View in: PubMed
    83. Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):103-13.
      View in: PubMed
    84. Liotta LA, Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S25-8; discussion S37-42.
      View in: PubMed
    85. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF, Liotta LA. Biomarker amplification by serum carrier protein binding. Dis Markers. 2003-2004; 19(1):1-10.
      View in: PubMed
    86. Johann DJ, McGuigan MD, Tomov S, Fusaro VA, Ross S, Conrads TP, Veenstra TD, Fishman DA, Whiteley GR, Petricoin EF, Liotta LA. Novel approaches to visualization and data mining reveals diagnostic information in the low amplitude region of serum mass spectra from ovarian cancer patients. Dis Markers. 2003-2004; 19(4-5):197-207.
      View in: PubMed
    87. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res. 2002 Nov; 8(11):3324-31.
      View in: PubMed
    88. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002 Sep 15; 62(18):5358-64.
      View in: PubMed
    89. Pangas SA, Rademaker AW, Fishman DA, Woodruff TK. Localization of the activin signal transduction components in normal human ovarian follicles: implications for autocrine and paracrine signaling in the ovary. J Clin Endocrinol Metab. 2002 Jun; 87(6):2644-57.
      View in: PubMed
    90. Hendrickson BC, Nielsen DR, Gaglio CA, Wonderlick A, Fishman DA, Frank TS, Scholl T. Interpreting three new and unique BRCA1 mutations in an Ashkenazi Jewish patient. Clin Genet. 2002 Apr; 61(4):317-8.
      View in: PubMed
    91. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002 Feb 16; 359(9306):572-7.
      View in: PubMed
    92. Cohen L, Fishman DA. Ultrasound and ovarian cancer. Cancer Treat Res. 2002; 107:119-32.
      View in: PubMed
    93. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res. 2002; 107:259-83.
      View in: PubMed
    94. Bast RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002; 107:61-97.
      View in: PubMed
    95. Fishman DA, Bozorgi K. The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). Cancer Treat Res. 2002; 107:3-28.
      View in: PubMed
    96. Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, Ernsberger P. The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem. 2001 Dec; 79(5):931-40.
      View in: PubMed
    97. Devereux RB, Bella JN, Palmieri V, Oberman A, Kitzman DW, Hopkins PN, Rao DC, Morgan D, Paranicas M, Fishman D, Arnett DK. Left ventricular systolic dysfunction in a biracial sample of hypertensive adults: The Hypertension Genetic Epidemiology Network (HyperGEN) Study. Hypertension. 2001 Sep; 38(3):417-23.
      View in: PubMed
    98. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol. 2001 Jul; 82(1):40-8.
      View in: PubMed
    99. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001 May 12; 357(9267):1467-70.
      View in: PubMed
    100. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001 Apr 1; 61(7):3194-9.
      View in: PubMed
    101. Fishman D, Irena B, Kellman-Pressman S, Karas M, Segal S. The role of MHC class I glycoproteins in the regulation of induction of cell death in immunocytes by malignant melanoma cells. Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4):1740-4.
      View in: PubMed
    102. Jones EC, Devereux RB, Roman MJ, Liu JE, Fishman D, Lee ET, Welty TK, Fabsitz RR, Howard BV. Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study). Am J Cardiol. 2001 Feb 1; 87(3):298-304.
      View in: PubMed
    103. Zuppiroli A, Mori F, Favilli S, Dolara A, Roman MJ, Fishman D, Devereux RB. "Natural histories" of mitral valve prolapse. Influence of patient selection on cardiovascular event rates. Ital Heart J. 2001 Feb; 2(2):107-14.
      View in: PubMed
    104. Fishman D, Burnand B, Dorta G, Wassserfallen JB. [Upper gastrointestinal hemorrhage, initial management: clinical practice recommendations]. Rev Med Suisse Romande. 2001 Jan; 121(1):65-84.
      View in: PubMed
    105. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001; 6(5):441-5.
      View in: PubMed
    106. Small W, Mahadevan A, Roland P, Vallow L, Zusag T, Fishman D, Massad S, Rademaker A, Kalapurakal JA, Chang S, Lurain J. Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival. Cancer J. 2000 Nov-Dec; 6(6):394-400.
      View in: PubMed
    107. Fishman DA, Cohen LS. Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma? Gynecol Oncol. 2000 Jun; 77(3):347-9.
      View in: PubMed
    108. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000 Apr; 66(4):1259-72.
      View in: PubMed
    109. Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer. 2000; 36(1):101-11.
      View in: PubMed
    110. Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G, Paranicas M, Fishman D, Devereux RB. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol. 1999 Nov 1; 34(5):1625-32.
      View in: PubMed
    111. Fishman DA, Kearns A, Larsh S, Enghild JJ, Stack MS. Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment. Biochem J. 1999 Aug 1; 341 ( Pt 3):765-9.
      View in: PubMed
    112. Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM, Stack MS. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 1999 Apr 1; 59(7):1635-41.
      View in: PubMed
    113. Calhoun EA, Bennett CL, Peeples PA, Lurain JR, Roland PY, Weinstein JM, Fishman DA. Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol. 1998 Dec; 71(3):369-75.
      View in: PubMed
    114. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998 Oct 1; 102(7):1369-76.
      View in: PubMed
    115. Abrahamson J, Moslehi R, Vesprini D, Karlan B, Fishman D, Smotkin D, Ben David Y, Biran H, Fields A, Brunet JS, Narod SA. No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. Cancer Res. 1998 Jul 15; 58(14):2919-22.
      View in: PubMed
    116. Fishman DA, Padilla LA, Joob A, Lurain JR. Ectopic pregnancy causing hemothorax managed by thoracoscopy and actinomycin D. Obstet Gynecol. 1998 May; 91(5 Pt 2):837-8.
      View in: PubMed
    117. Fishman DA, Padilla LA, Keh P, Cohen L, Frederiksen M, Lurain JR. Management of twin pregnancies consisting of a complete hydatidiform mole and normal fetus. Obstet Gynecol. 1998 Apr; 91(4):546-50.
      View in: PubMed
    118. Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol. 1998 Mar; 12(3):569-76.
      View in: PubMed
    119. Fishman DA, Kearns A, Chilukuri K, Bafetti LM, O'Toole EA, Georgacopoulos J, Ravosa MJ, Stack MS. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis. 1998; 18(1):15-26.
      View in: PubMed
    120. Fishman D, Galitzki L, Priel E, Segal S. Epidermal growth factor regulates protein kinase A activity in murine fibrosarcoma cells: differences between metastatic and nonmetastatic tumor cell variants. Cancer Res. 1997 Dec 1; 57(23):5410-5.
      View in: PubMed
    121. Fishman DA, Chilukuri K, Stack MS. Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity. Gynecol Oncol. 1997 Nov; 67(2):193-9.
      View in: PubMed
    122. Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, Stack MS. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer. 1997 Oct 15; 80(8):1457-63.
      View in: PubMed
    123. Ollendorff AT, Keh P, Hoff F, Lurain JR, Fishman DA. Leiomyoma causing massive ascites, right pleural effusion and respiratory distress. A case report. J Reprod Med. 1997 Sep; 42(9):609-12.
      View in: PubMed
    124. Fishman D, Wolfson M, Bazarski E, Segal S, Rager-Zisman B. The effects of measles virus persistent infection on AP-1 transcription factor binding in neuroblastoma cells. FEBS Lett. 1997 Jun 30; 410(2-3):191-4.
      View in: PubMed
    125. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y. Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells. J Biol Chem. 1997 Jun 27; 272(26):16514-20.
      View in: PubMed
    126. Kushner DM, Zak RD, Lurain JR, Fishman DA. Ovarian carcinoma metastatic to the choroid of the eye. Gynecol Oncol. 1997 Jun; 65(3):517-9.
      View in: PubMed
    127. Kushner DM, Lurain JR, Fu TS, Fishman DA. Endometrial adenocarcinoma metastatic to the scalp: case report and literature review. Gynecol Oncol. 1997 Jun; 65(3):530-3.
      View in: PubMed
    128. Hockstein S, Keh P, Lurain JR, Fishman DA. Ovarian carcinoma initially presenting as metastatic axillary lymphadenopathy. Gynecol Oncol. 1997 Jun; 65(3):543-7.
      View in: PubMed
    129. Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer. 1996 Sep 4; 67(5):695-701.
      View in: PubMed
    130. Fishman DA, Williams S, Small W, Keh P, Gerbie MV, Schwartz PE, Gershenson DM, Lurain JR. Late recurrences of vaginal clear cell adenocarcinoma. Gynecol Oncol. 1996 Jul; 62(1):128-32.
      View in: PubMed
    131. Fishman DA, Roberts KB, Chambers JT, Kohorn EI, Schwartz PE, Chambers SK. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol. 1996 May; 61(2):189-96.
      View in: PubMed
    132. MacDonald SR, Lurain JR, Hoff F, Variakojis D, Fishman DA. Castleman disease presenting as a pelvic mass. Obstet Gynecol. 1996 May; 87(5 Pt 2):875-7.
      View in: PubMed
    133. Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis. 1996; 16(3):150-9.
      View in: PubMed
    134. Fishman DA, Viscarello RR, Cass I, Schwartz PE. Effect of combination chemotherapy with cisplatin and cyclophosphamide on human immunodeficiency virus type-1 surrogate markers in a patient with advanced epithelial ovarian cancer. Gynecol Oncol. 1995 Apr; 57(1):105-8.
      View in: PubMed
    135. Fishman DA, Chambers SK, Schwartz PE, Kohorn EI, Chambers JT. Extramammary Paget's disease of the vulva. Gynecol Oncol. 1995 Feb; 56(2):266-70.
      View in: PubMed
    136. Fishman DA, Schwartz PE. Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Curr Opin Obstet Gynecol. 1994 Feb; 6(1):98-104.
      View in: PubMed
    137. Feola M, Simoni J, Fishman D, Tran R, Canizaro PC. Biocompatibility of hemoglobin solutions. I. Reactions of vascular endothelial cells to pure and impure hemoglobins. Artif Organs. 1989 Jun; 13(3):209-15.
      View in: PubMed
    138. Wandel T, Fishman D, Novack GD, Kelley E, Chen KK. Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily. Ophthalmology. 1988 Feb; 95(2):252-5.
      View in: PubMed
    Fishman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067